Queiroz Karla C S, Shi Kun, Duitman JanWillem, Aberson Hella L, Wilmink Johanna W, van Noesel Carel J M, Richel Dick J, Spek C Arnold
Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Int J Cancer. 2014 Nov 15;135(10):2294-304. doi: 10.1002/ijc.28726. Epub 2014 Jun 19.
Protease activated receptor (PAR)-1 expression in tumor cells is associated with disease progression and overall survival in a variety of cancers of epithelial origin; however, the importance of PAR-1 in the tumor microenvironment remains unexplored. Utilizing an orthotopic pancreatic cancer model in which tumor cells are PAR-1 positive whereas stromal cells are PAR-1 negative, we show that PAR-1 expression in the microenvironment drives progression and induces chemoresistance of pancreatic cancer. PAR-1 enhances monocyte recruitment into the tumor microenvironment by regulating monocyte migration and fibroblast dependent chemokine production thereby inducing chemoresistance. Overall, our data identify a novel role of PAR-1 in the pancreatic tumor microenvironment and suggest that PAR-1 may be an attractive target to reduce drug resistance in pancreatic cancer.
蛋白酶激活受体(PAR)-1在肿瘤细胞中的表达与多种上皮源性癌症的疾病进展和总生存期相关;然而,PAR-1在肿瘤微环境中的重要性仍未得到探索。利用一种原位胰腺癌模型,其中肿瘤细胞PAR-1呈阳性而基质细胞PAR-1呈阴性,我们发现微环境中PAR-1的表达驱动胰腺癌进展并诱导化疗耐药。PAR-1通过调节单核细胞迁移和成纤维细胞依赖性趋化因子产生来增强单核细胞向肿瘤微环境的募集,从而诱导化疗耐药。总体而言,我们的数据确定了PAR-1在胰腺肿瘤微环境中的新作用,并表明PAR-1可能是降低胰腺癌耐药性的一个有吸引力的靶点。